Patents Assigned to Chiron Corporation
  • Method for administering a cytokine to the central nervous system and the lymphatic system
    Patent number: 6991785
    Abstract: The present invention is directed to a method for delivering cytokines to the central nervous system and the lymphatic system by way of a tissue innervated by the trigeminal nerve and/or olfactory nerve. Cytokines include tumor necrosis factors, interleukins, interferons, particularly interferon-? and its muteins such as IFN-?ser17. Such a method of delivery can be useful in the treatment of central nervous system disorders, brain disorders, proliferative, viral, and/or autoimmune disorders such as Sjogren's disorder.
    Type: Grant
    Filed: March 20, 2002
    Date of Patent: January 31, 2006
    Assignee: Chiron Corporation
    Inventor: William H. Frey, II
  • Carbocycle based inhibitors of glycogen synthase kinase 3
    Patent number: 6989382
    Abstract: New carbocyclic compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease, other neurodegenerative disorders, such as Parkinson's disease and Huntington's disease, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
    Type: Grant
    Filed: October 20, 2003
    Date of Patent: January 24, 2006
    Assignee: Chiron Corporation
    Inventors: Allan S. Wagman, Sharadha Subramanian, John M. Nuss
  • Immunogenic Hepatitis C virus non-structural polypeptides
    Patent number: 6986892
    Abstract: Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupt the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are also disclosed.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: January 17, 2006
    Assignee: Chiron Corporation
    Inventors: Doris Coit, Angelica Medina-Selby, Mark Selby, Michael Houghton
  • Dose of an angiogenic factor and method of administering to improve myocardial blood flow
    Publication number: 20060009390
    Abstract: The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis.
    Type: Application
    Filed: September 6, 2005
    Publication date: January 12, 2006
    Applicants: Chiron Corporation, Duke University
    Inventors: David Hung, Brian Annex, Kevin Landolfo, W. Kavanaugh
  • Stabilized interferon compositions
    Publication number: 20060008447
    Abstract: Stabilized pharmaceutical formulations comprising IFN-? and highly purified mannitol are provided. The highly purified mannitol stabilizes the compositions by reducing the formation of IFN-? adducts in comparison with IFN-? formulated with mannitol that has not been highly purified. Methods for increasing the stability of IFN-? or a variant thereof in a liquid or lyophilized composition and for increasing storage stability of such a composition are also provided.
    Type: Application
    Filed: July 22, 2005
    Publication date: January 12, 2006
    Applicant: Chiron Corporation
    Inventors: Sidney Wolfe, Maninder Hora
  • Monobactam compositions and methods of use thereof
    Publication number: 20060003984
    Abstract: Methods, compounds and compositions are provided for inhibiting the growth of pathogenic microbes in vitro and of treatment of pathogenic bacterial infections in vivo using an antibacterial monobactam compound and a mucolytic agent.
    Type: Application
    Filed: August 25, 2005
    Publication date: January 5, 2006
    Applicant: Chiron Corporation
    Inventor: Ribhi Shawar
  • Method of complexing a nucleic acid with a lipid-conjugated polyamide
    Patent number: 6982092
    Abstract: In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: January 3, 2006
    Assignee: Chiron Corporation
    Inventors: Ronald N. Zuckermann, Chin-Yi Huang, John E. Murphy, Tetsuo Uno
  • Meningococcal antigens
    Publication number: 20050287165
    Abstract: The invention provides proteins from Neisseria meningitidis (strains A & B), including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.
    Type: Application
    Filed: August 24, 2005
    Publication date: December 29, 2005
    Applicant: Chiron Corporation
    Inventors: Vincenzo Scarlato, Vega Masignani, Rino Rappuoli, Mariagrazia Pizza, Guido Grandi
  • Enhancing immune responses to genetic immunization by using a chemokine
    Publication number: 20050281779
    Abstract: The immune response to a DNA immunogen in a mammal can be enhanced by administration of a chemokine or a polynucleotide encoding the chemokine. This method can be used, for example, to immunize or vaccinate a mammal against an infectious disease or a tumor.
    Type: Application
    Filed: March 29, 2005
    Publication date: December 22, 2005
    Applicant: Chiron Corporation
    Inventor: Xavier Paliard
  • Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
    Patent number: 6974867
    Abstract: Inhibitors of KIAA0175 are provided that reduce the expression or biological activities of KIAA0175, p53 and/or p21 in a mammalian cell. KIAA0175 inhibitors include anti-sense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. KIAA0175 inhibitors find use in compositions and methods for decreasing KIAA0175, p53 and/or p21 gene expression as well as methods for increasing the chemo and/or radiosensitivity of mammalian cells, including tumor cells, methods for decreasing the side effects of cancer therapy and methods for treating neoplastic diseases.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: December 13, 2005
    Assignee: Chiron Corporation
    Inventors: Bin Wu, Todd W. Seeley, Lewis T. Williams
  • Novel IGF-1 composition and its use
    Publication number: 20050266046
    Abstract: A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to about 1.2 g/ml, and a viscosity of about 13,000 centipoise (cps) to about 19,000 cps, as measured at ambient temperature (23° C.). The IGF-I syrup is prepared by precipitating or partitioning IGF-I from solution, preferably by adjusting the solution pH or by use of a solubility enhancer to concentrate IGF-I in solution followed by removal of the solubility enhancer. The precipitated syrup is useful as a means of storing IGF-I in a stable form and as a means of preparing compositions comprising biologically active IGF-I. Pharmaceutical compositions and kits comprising this concentrated IGF-I syrup are provided.
    Type: Application
    Filed: August 2, 2005
    Publication date: December 1, 2005
    Applicant: Chiron Corporation
    Inventors: Bret Shirley, Maninder Hora
  • HCV E1E2 vaccine compositions
    Publication number: 20050255124
    Abstract: HCV E1E2 compositions comprising E1E2 antigens, submicron oil-in-water emulsions and/or immunostimulatory nucleic acid sequences are described. The compositions can be used in methods of stimulating an immune response in a vertebrate subject.
    Type: Application
    Filed: June 16, 2005
    Publication date: November 17, 2005
    Applicant: Chiron Corporation
    Inventors: Michael Hougton, Stephen Coates, Derek O'Hagan, Yiu-Lian Fong
  • Substituted 2,5-heterocyclic derivatives
    Publication number: 20050256121
    Abstract: The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: March 30, 2005
    Publication date: November 17, 2005
    Applicant: Chiron Corporation
    Inventors: Anne Jefferson, Xiaodong Lin, Xiaojing Wang, Alice Rico, Annette Walter, Yasheen Zhou
  • Combination PDGF, KGF, IGF, and IGFBP for wound healing
    Publication number: 20050250695
    Abstract: The invention provides a therapeutic composition for epithelial wound repair that is a combination of PDGF and KGF. Further, the invention provides a composition for epithelial wound repair that is a therapeutic combination of PDGF, KGF, and IGF. Additionally, the invention provides a therapeutic composition of PDGF, KGF, IGF and IGFBP for epithelial wound repair.
    Type: Application
    Filed: May 2, 2005
    Publication date: November 10, 2005
    Applicant: Chiron Corporation
    Inventor: Lewis Williams
  • Guanidino compounds
    Patent number: 6960582
    Abstract: Compounds having the general structure II are provided: A is selected from the group consisting of C or CH and X and Y are independently selected from the group consisting of CH2, N, C?O, C?S, (CR6R7)n, S?O, SO2, O, NR9, S, C(?O)—(CR6R7)n, and C(?S)—(CR6R7)n where n is 1, 2, or 3. W is selected from the group consisting of and Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. L is selected from the group consisting of N, O, S, S?O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Compounds of formula II are agonists of the melanocortin-4 receptor (“MC4-R”) and therefore may have useful properties for controlling diseases related to MC4-R action in humans, such as obesity and type II diabetes.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: November 1, 2005
    Assignee: Chiron Corporation
    Inventors: Rustum Boyce, David Duhl
  • Meningococcus adhesins nada, app and orf 40
    Publication number: 20050232936
    Abstract: NadA, App and ORF40 function as adhesins in N. meningitidis. Adhesion can be modulated by targeting these three proteins. NadA allelic variants are disclosed. Autoproteolytic cleavage of App is disclosed, as is removal of the activity by mutagenesis. App is processed and secreted into culture medium when expressed in E. coli. Mature App proteins are disclosed. Knockout mutants are disclosed. Vesicles from non-Neisserial hosts with heterologous adhesin expression are disclosed.
    Type: Application
    Filed: July 26, 2002
    Publication date: October 20, 2005
    Applicant: CHIRON CORPORATION
    Inventors: Maria Arico, Maurizio Comanducci
  • Use of hyaluronic acid polymers for mucosal delivery of vaccine and adjuvants
    Publication number: 20050226937
    Abstract: Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the compositions, as well as methods of immunization using the same.
    Type: Application
    Filed: November 30, 2004
    Publication date: October 13, 2005
    Applicant: Chiron Corporation
    Inventors: Derek O'Hagan, Alessandra Pavesio
  • Mitotic kinesin inhibitors
    Publication number: 20050228002
    Abstract: The present invention relates to compounds that are useful for treating cellular proliferative diseases, for treating disorders mediated, at least in part, by KSP, and for inhibiting KSP. The invention also related to pharmaceutical compositions comprising such compounds, methods of treating cancer by the administration of such compositions, and processes for the preparation of the compounds.
    Type: Application
    Filed: April 6, 2005
    Publication date: October 13, 2005
    Applicant: Chiron Corporation
    Inventors: Weibo Wang, Ryan Constantine, Liana Lagniton
  • Method of increasing product expression through solute stress
    Publication number: 20050221393
    Abstract: A method of determining the optimal level of product expression and cell growth of animal cell culture is described. The method generally comprises culturing cells under conditions of solute stress, that is, under conditions whereby optimal cell growth or growth rate is decreased yet levels of product expression are increased. In a preferred embodiment of the invention is described a method of increasing the yield of monoclonal antibodies comprising culturing hybridoma cells in an environment of solute stress. One approach to the creation of such an environment is the addition of inorganic salts, organic polyols, or metabolic products to the culture medium. One- to three-fold increases in antibody yield have been obtained by these methods.
    Type: Application
    Filed: May 9, 2005
    Publication date: October 6, 2005
    Applicant: Chiron Corporation
    Inventors: Brian Maiorella, Duane Inlow, William Howarth
  • Diagnostic assays for parvovirus B19
    Publication number: 20050221300
    Abstract: Human parvovirus B19 primers and probes derived from conserved regions of the parvovirus B19 genome are disclosed. Also disclosed are nucleic acid-based assays using the primers and probes.
    Type: Application
    Filed: May 23, 2005
    Publication date: October 6, 2005
    Applicant: Chiron Corporation
    Inventors: Sergio Pichuantes, Venkatakrishna Shyamala